VRTX
NASDAQ · Biotechnology
Vertex Pharmaceuticals Inc
$508.33
-8.11 (-1.57%)
Financial Highlights (FY 2026)
Revenue
11.68B
Net Income
3.85B
Gross Margin
86.2%
Profit Margin
32.9%
Rev Growth
+10.4%
D/E Ratio
0.01
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 86.2% | 86.2% | 56.9% | 56.9% |
| Operating Margin | 34.8% | 31.3% | 11.0% | 10.1% |
| Profit Margin | 32.9% | 31.3% | 8.5% | 11.0% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 11.68B | 10.58B | 15.93B | 17.43B |
| Gross Profit | 10.07B | 9.12B | 9.06B | 9.91B |
| Operating Income | 4.06B | 3.31B | 1.76B | 1.76B |
| Net Income | 3.85B | 3.14B | 1.35B | 1.92B |
| Gross Margin | 86.2% | 86.2% | 56.9% | 56.9% |
| Operating Margin | 34.8% | 31.3% | 11.0% | 10.1% |
| Profit Margin | 32.9% | 31.3% | 8.5% | 11.0% |
| Rev Growth | +10.4% | +10.4% | -6.3% | +21.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 371.32M | 371.32M | 13.83B | 14.35B |
| Total Equity | 61.89B | 61.89B | 91.42B | 88.18B |
| D/E Ratio | 0.01 | 0.01 | 0.15 | 0.16 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 4.26B | 3.67B | 2.28B | 2.59B |
| Free Cash Flow | — | — | 1.35B | 2.40B |